Board Change • May 20
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairperson of the Board Lindley Edwards is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Feb 16
Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8 million. Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 160,000,000
Price\Range: AUD 0.005
Discount Per Security: AUD 0.0003
Transaction Features: Subsequent Direct Listing Tillkännagivande • Feb 06
Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.8 million. Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 160,000,000
Price\Range: AUD 0.005
Discount Per Security: AUD 0.0003
Transaction Features: Subsequent Direct Listing Tillkännagivande • Dec 30
Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.120549 million. Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.120549 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 180,460,810
Price\Range: AUD 0.003
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 193,055,540
Price\Range: AUD 0.003
Security Features: Attached Options
Transaction Features: Rights Offering Tillkännagivande • Oct 21
Memphasys Limited, Annual General Meeting, Nov 20, 2025 Memphasys Limited, Annual General Meeting, Nov 20, 2025. Location: at level 32, 200 george street, sydney nsw 2000 Australia Tillkännagivande • Oct 20
Memphasys Limited Announces Board Changes, Effective 20 October 2025 Memphasys Limited announced that Dr. David Ali will step down as Executive Director effective 20 October 2025. Dr. Ali will continue in his role as Chief Executive Officer (CEO), with a dedicated focus on the operational and executional aspects of the business as the Company advances the commercialisation of the FelixTM System. This change reflects Memphasys' strategic pivot toward commercialisation, marking a transition from product development to global market rollout. With multiple distribution agreements progressing and CE marking expected in early 2026, operational discipline and execution have become central to the Company's success. Concentrating Dr. Ali's focus solely on operations will ensure optimal delivery against these commercial milestones. As part of this evolution, Mr. Marjan Mikel has assumed the role of Chair of Commercialisation, overseeing strategy, partnerships, and market expansion initiatives. This reinforces the Company's commitment to disciplined growth, partnership-driven scaling, and commercial excellence. The company also announced the appointment of Mr. Mathew Watkins as an Independent Non- Executive Director, effective 20 October 2025. Mr. Watkins is a Chartered Accountant and member of the Governance Institute of Australia with extensive ASX experience across biotechnology, bioscience, resources, and information technology sectors. He specialises in ASX statutory reporting, compliance, corporate governance, and board and secretarial support. Mr. Watkins serves as Company Secretary for several ASX-listed entities and is currently the SEA Regional Practice Lead & Australia Market Lead at Vistra (Australia) Pty Ltd. Tillkännagivande • Oct 04
Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.120549 million. Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.120549 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 373,516,350
Price\Range: AUD 0.003
Transaction Features: Rights Offering Tillkännagivande • Sep 23
Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8925 million. Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8925 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 297,500,000
Price\Range: AUD 0.003
Discount Per Security: AUD 0.00018
Transaction Features: Subsequent Direct Listing Tillkännagivande • Jun 20
Memphasys Limited Appoints Marjan Mikel as Non-Executive Director Memphasys Limited announced the appointment of Mr. Marjan Mikel as a Non-Executive Director of the Company, effective immediately. Mr. Mikel brings a strong and diverse track record in business development, commercial leadership, capital markets, and strategic partnership execution across the Medtech, diagnostics, healthcare services, and life sciences sectors. He has held senior executive and board positions in both listed and private companies, with extensive experience in the commercialization of disruptive technologies and scaling ventures in regulated markets. He is currently the CEO and Managing Director of Vitasora Health Limited, an ASX-listed remote patient monitoring company operating in the U.S. healthcare system. Under his leadership, the company has pioneered the commercialization of a novel respiratory monitoring device and successfully transitioned into a full-service RPM provider. Mr. Mikel led capital raises, secured major U.S. ACO and payer contracts, and executed the cross-border acquisition of U.S.-based Orb Health, expanding the company's footprint and capabilities in the U.S. market. Previously, Mr. Mikel founded Healthy Sleep Solutions, building it into Australia's largest sleep health provider before securing ResMed as a strategic investor and leading a successful trade sale to global multinational Air Liquide. He also held senior commercial roles with IMS Health, Merck Sharp & Dohme, Pharmacia, and Searle, with responsibilities across Australia, Asia-Pacific, and Europe. Importantly, Mr. Mikel is familiar with Memphasys and its strategic vision, having previously served as a Non-Executive Director of the Company from June 2018 to March 2020, including as Chair of both the Audit & Risk Committee and the Nomination & Remuneration Committee. Mr. Mikel holds a Master of Commerce from the University of New South Wales, a Graduate Diploma in Education, and a Bachelor of Science (Hons) from the University of Sydney and has completed executive studies at the Australian Graduate School of Management. He is also a Member of the Australian Institute of Company Directors (MAICD). Tillkännagivande • Apr 17
Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2755 million. Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2755 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 212,583,334
Price\Range: AUD 0.006
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Apr 10
Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.275 million. Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.275 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 212,500,000
Price\Range: AUD 0.006
Transaction Features: Subsequent Direct Listing Tillkännagivande • Sep 25
Memphasys Limited, Annual General Meeting, Oct 25, 2024 Memphasys Limited, Annual General Meeting, Oct 25, 2024. Location: level 1, 34-36 richmond road, homebush west nsw 2140, Australia New Risk • Sep 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (55% average daily change). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m (AU$1.3m revenue, or US$855k). Market cap is less than US$10m (€7.91m market cap, or US$8.73m). Reported Earnings • Sep 01
Full year 2024 earnings released Full year 2024 results: Net loss: AU$4.44m (loss widened 31% from FY 2023). Tillkännagivande • Aug 30
Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million. Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 62,500,000
Price\Range: AUD 0.008
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Jul 29
Memphasys Limited announced that it has received AUD 0.5 million in funding Memphasys Limited entered into a subscription agreement with Andrew Goodall for issuance of 62,500,000 common shares at a price of AUD 0.008 per share for gross proceeds of AUD 500,000 on July 29, 2024. New Risk • Feb 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.8m free cash flow). Share price has been highly volatile over the past 3 months (71% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (AU$656k revenue, or US$429k). Market cap is less than US$10m (€8.24m market cap, or US$8.95m). Minor Risk Shareholders have been diluted in the past year (43% increase in shares outstanding). Tillkännagivande • Jan 10
Memphasys Limited, Annual General Meeting, Feb 14, 2024 Memphasys Limited, Annual General Meeting, Feb 14, 2024, at 10:00 AUS Eastern Standard Time. Location: 30 Richmond Road, Homebush West New South Wales Australia Agenda: To consider APPROVAL OF ISSUE OF SHARES TO PETERS INVESTMENTS ON CONVERSION OF CONVERTIBLE NOTES; to consider APPROVAL TO ISSUE OPTIONS FREE ATTACHING TO PLACEMENT SHARES; to consider APPROVAL TO ISSUE SHARES AND OPTIONS TO RELATED PARTY UNDER THE PLACEMENT ON CONVERSION OF SHORT-TERM LOANS MR ANDREW GOODALL; and to discuss other matters. New Risk • Dec 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (75% average weekly change). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (AU$624k revenue, or US$411k). Market cap is less than US$10m (€8.27m market cap, or US$8.93m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). Tillkännagivande • Dec 04
Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 4.232268 million. Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 4.232268 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 210,000,000
Price\Range: AUD 0.01
Discount Per Security: AUD 0.0006
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 213,226,752
Price\Range: AUD 0.01
Discount Per Security: AUD 0.0006
Security Features: Attached Options
Transaction Features: Rights Offering; Subsequent Direct Listing Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2022) Full year 2023 results: AU$0.002 loss per share. Net loss: AU$3.40m (loss widened 63% from FY 2022). Tillkännagivande • Aug 31
Memphasys Limited, Annual General Meeting, Nov 22, 2023 Memphasys Limited, Annual General Meeting, Nov 22, 2023, at 11:00 E. Australia Standard Time. Location: 30 Richmond Road, 2140 Homebush West New South Wales Australia New Risk • Aug 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m (AU$72k revenue, or US$46k). Market cap is less than US$10m (€9.11m market cap, or US$9.84m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (10% increase in shares outstanding). New Risk • Jun 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.87m (US$9.72m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m (AU$72k revenue, or US$49k). Market cap is less than US$10m (€8.87m market cap, or US$9.72m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding). Tillkännagivande • Feb 07
Memphasys Limited Announces the First Publications of Study Findings by Key Opinion Leaders (KOLs) of the Felix System Memphasys Limited announced the first publications of study findings by key opinion leaders (KOLs) of the Felix System - a patented, automated device for quickly and gently separating high quality sperm from a semen sample for use in human IVF procedures. A published article entitled "Spermatozoa isolation with Felix outperforms conventional density gradient centrifugation preparation in selecting cells with low DNA damage" featured in Andrology, the official journal of the American society of Andrology and European Academy of Andrology, on 11th January 2023. The research was conducted by renowned French genetics reproduction and development lab (GReD), supported by the University Clermont Auvergne (UCA), and led by Professor Joel Drevet, an international leader in mammalian andrology ("the KOL"). The KOL studied 29 human semen samples which were analysed fresh and after DGC or Felix System preparation and were monitored by sample volume, sperm count, total motility, progressive motility, sperm DNA fragmentation using the Sperm Chromatin Structure Assay ("SCSA") and sperm DNA oxidation. Results of the study highlighted spermatozoa preparation with Felix System "significantly improved spermatozoa fractions with higher progressive motility, lower sperm DNA fragmentation, and lower sperm DNA oxidation compared with raw semen and DGC-prepared spermatozoa". The article noted that the study data supported spermatozoa preparation by the Felix system "as it allows selection of spermatozoa with the highest progressive motility as well as the lowest nuclear/DNA damage." The article concluded that "These improved sperm parameters, along with the fact that the Felix separation process is very fast and highly standardized, should be of great interest to the assisted reproduction technologies industry." In addition, another article entitled "A comparison between the Felix electrophoretic system of sperm isolation and conventional density gradient centrifugation: a multicentre analysis", has been published in Journal of Assisted Reproduction and Genetics, an official journal of the American Society for Reproductive Medicine. Supported by Memphasys, the research was conducted and collaborated across five KOLs namely: Monash IVF, Australia; Andrology Center, India; The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, USA; GeneraLife IVF, Sweden; Reproductive and Genetic Hospital, People's Republic of China. The KOLs compared the quality of the sperm populations isolated by the Felix System and DGC in terms of processing time, sperm concentration, motility, vitality, and DNA integrity as assessed by 3 methods: SCSA, Halo, and TUNEL. Across all KOLs, 112 comparisons were performed with findings highlighting the Felix system "is a positive technical development capable of isolating suspensions of highly motile spermatozoa in a fraction of the time taken by conventional procedures such as DGC." Four of the five centres reported a significant improvement in DNA integrity relative to DGC (one reported no statistical difference but both methods selected sperm with low DNA damage). The Felix system isolates sperm in a standardised 6-minute preparation time whereas clinical DGC protocols vary between sites but generally took around 40 minutes to complete. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Aug 18
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • May 04
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • May 27
Memphasys Limited announced that it expects to receive AUD 3 million in funding from Peters Investments Proprietary Ltd., and another investor Memphasys Limited (ASX:MEM) announced a private placement of 50,000,000 convertible notes at a price of AUD 0.060 per note for gross proceeds of AUD 3,000,000 on May 26, 2021. The transaction will include participation from existing investor Peters Investments Proprietary Ltd for AUD 1,650,000 and non-executive director Andrew Goodall for AUD 1,350,000. The notes are unsecured, will bear an interest rate of 8% per annum, and will be repayable on December 31, 2022. The notes will be converted into common shares of the company at a conversion price of AUD 0.06 and a 20% discount to the issue price of shares and/or the exercise price of any options offered under any capital raising(s) completed by the Company of greater than AUD 1,000,000 prior to the Repayment Date. The facilitation fee of 3% of gross value of convertible notes, to be added to the gross value of the convertible notes. The company will also issue 3,000,000 options at a price of AUD 0.060 per option in the transaction. The options will expire on December 31, 2023. The transaction is subject to shareholders meeting to be held on July 9, 2021 and regulatory approvals. The transaction is expected to close on July 9, 2021. 